Managing Unclear Cancer Diagnoses: Expert Perspectives from Leaders in Pathology and Oncology
Presented by: Dr. F. Anthony Greco; Co-Founder, Sarah Cannon Research Institute; Medical Oncologist, Tennessee Oncology; and Medical Advisor, Biotheranostics; and Dr. Lawrence M. Weiss, Chief Scientific Officer at NeoGenomics Laboratories
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R)
NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter
NeoGenomics Completes Acquisition of Genoptix, Inc.
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
A New Level of Service for Diagnosing Hematologic Malignancies
for a complex disease spectrum
Now also available through NeoGenomics - for unclear or unknown diagnoses in solid tumors
Performed and billed separately by our contracted reference laboratory, Biotheranostics, Inc.